In the Spotlight

Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices

Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team

The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies  

According to the 2022 awardee, the future of immuno-oncology lies in the modulation of the tumour microenvironment and cancer vaccines 

Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities

Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients

ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach 

Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance 

In neighbouring countries, oncologists are seeing a growing number of female refugees with breast cancer whose treatment may have started before they left Ukraine and urgently needs to be continued for good outcomes to be achieved. 

In her Keynote Lecture at ESMO Breast Cancer 2022, Prof. Sibylle Loibl looks at neoadjuvant therapy and the fertility and pregnancy issues facing young women with breast cancer